Chapters Transcript Video Key Takeaways from 2021 ACC Scientific Sessions Cardiologist Garima Sharma shares key takeaways from the 2021 ACC Scientific Sessions. Hi everyone. My name is Gary musameh. I am a cardiologist at johns Hopkins at the Check only Center for Prevention of Cardiovascular disease and I'm here to give you a quick update about the A. C. C. 21 scientific sessions that happened virtually um currently are on demand On May 15 to May 17. I think the biggest take home for me from the sessions were that they were virtual um and allow the attendees the flexibility to listen to them on demand. Which is always great. But I also missed the personal connection of meeting friends and uh you know colleagues and um seeing folks outside of work and unfortunately did not happen this year. Hopefully next year. Um I think for me the biggest take homes were the entire platform had more than 300 sessions. There was a wide variety, many of them were multidisciplinary which was very good to see with very good proportion of uh clinical trials and sessions based on clinical trials and late breakers. As well as evolving and barging subspecialties within cardiology such as cardio obstetrics and women's cardiovascular health and cardio ecology and critical care cardiology. Which is great. I also thought that the integration of cardiovascular team management, nurse practitioners and pharmacists and sessions based on team members were particularly uh fantastic. And we're really geared towards improving clinical knowledge and competencies in many of these areas, particularly for me. I think there were four or five big clinical trials that stood out because I thought that they are going to be practice changing. Um And I also appreciated that these clinical trials were done during a very difficult time to do clinical trials when there is a global pandemic. So it really kudos to the principal investigators and the study team and the coordinators were able to finish these big landmark practice changing trials in the middle of a global pandemic. Um the things that stood out for me were the last three, which was the collusion of the left atrial appendage during surgery. I think that was a really good important practice changing trial. The adaptable study, which was the use of aspirin 81 mg works at 325 mg and second prevention of patients with cardiovascular disease where 81 mg is very feasible, did not have any poor outcomes and should be uh perfectly adequate um in the management of these patients. Um uh there was another trial um that came out on the quality of life and patients with hypertrophic cardiomyopathy. The Explorer at cm Trial with the use of this new drug, Medi Campton and also had clinical benefit. Um and so it was really good to see that there is now a new drug that can be used in patients, especially in those that have um severe obstructive symptoms and their quality of life is for. And then there are others that also come to my mind obviously you know um they're all now published either in the land set or journal American College of Cardiology, New England Journal. And they're also available on not online on a cc dot org. So um most folks can actually have access to that. Um And I would lastly I want to close with um the focus on sex and gender science um in our clinical trials. Me being somebody who focuses a lot of that in my in my clinical practice as well as research. I found that particularly meaningful. And I was very impressed that the land set devoted an entire commission uh to women's Cardiovascular Health which was presented by Dr Roxanne and Iran from Mount Sinai. And it was very interesting to see. So I took a lot out of that. Created by Related Presenters Garima Sharma, MBBS Assistant Professor of Medicine EXPERTISE Arrhythmia, Cardiac Imaging, Cardiac Rehabilitation, Cardiomyopathy, Cardio-Obstetrics, Cardiovascular Disease, Clinical Cardiology, Congestive Heart Failure (CHF), Coronary Artery Disease, Heart Disease Prevention and Treatment ... View full profile